ArticlePlant biotechnology journal2018
Immunogenicity of plant-produced African horse sickness virus-like particles: implications for a novel vaccine.
Article in Plant biotechnology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Development of an African horse sickness VP6 DIVA diagnostic ELISA.Virology journal · 2025Article
- Virus-like Particles Produced in Plants: A Promising Platform for Recombinant Vaccine Development.Plants (Basel, Switzerland) · 2024Review
- Getting Hold of the Tobamovirus Particle-Why and How? Purification Routes over Time and a New Customizable Approach.Viruses · 2024Review
- The Potential of Plant-Produced Virus-like Particle Vaccines for African Horse Sickness and Other Equine Orbiviruses.Pathogens (Basel, Switzerland) · 2024Review
- Immunogenic profile of a plant-produced nonavalent African horse sickness viral protein 2 (VP2) vaccine in IFNAR-/- mice.PloS one · 2024Article
- Review
- Plant-based biopharmaceutical engineering.Nature reviews bioengineering · 2023Review
- Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance.Vaccines · 2022Review
- Review
- Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers.Journal of nanobiotechnology · 2021Review
- African horse sickness in Thailand: Challenges of controlling an outbreak by vaccination.Equine veterinary journal · 2021Article
- Reverse genetics approaches: a novel strategy for African horse sickness virus vaccine design.Current opinion in virology · 2020Review
- Innovation in plant-based transient protein expression for infectious disease prevention and preparedness.Current opinion in biotechnology · 2020Review
- Article
- A Roadmap for the Molecular Farming of Viral Glycoprotein Vaccines: Engineering Glycosylation and Glycosylation-Directed Folding.Frontiers in plant science · 2020Review
- Plant-produced chimeric virus-like particles - a new generation vaccine against African horse sickness.BMC veterinary research · 2019Article
- Review
- IC-Tagging methodology applied to the expression of viral glycoproteins and the difficult-to-express membrane-bound IGRP autoantigen.Scientific reports · 2018Article
- Safety and immunogenicity of plant-produced African horse sickness virus-like particles in horses.Veterinary research · 2018Article
- Trigger factor assisted self-assembly of canine parvovirus VP2 protein into virus-like particles in Escherichia coli with high immunogenicity.Virology journal · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African horse sickness (AHS) is a debilitating and often fatal viral disease affecting horses in much of Africa, caused by the dsRNA orbivirus African horse sickness virus (AHSV). Vaccination remains the single most effective weapon in combatting AHS, as there is no treatment for the disease apart from good animal husbandry. However, the only commercially available vaccine is a live-attenuated version of the virus (LAV). The threat of outbreaks of the disease outside its endemic region and the fact that the LAV is not licensed for use elsewhere in the world, have spurred attempts to develop an alternative safer, yet cost-effective recombinant vaccine. Here, we report the plant-based production of a virus-like particle (VLP) AHSV serotype five candidate vaccine by Agrobacterium tumefaciens-mediated transient expression of all four capsid proteins in Nicotiana benthamiana using the cowpea mosaic virus-based HyperTrans (CPMV-HT) and associated pEAQ plant expression vector system. The production process is fast and simple, scalable, economically viable, and most importantly, guinea pig antiserum raised against the vaccine was shown to neutralize live virus in cell-based assays. To our knowledge, this is the first report of AHSV VLPs produced in plants, which has important implications for the containment of, and fight against the spread of, this deadly disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.